Abstract
Prior to 2006, M-M-R(®)II (measles, mumps, and rubella virus vaccine live) was manufactured using human serum albumin (HSA) and each dose of the vaccine contained a relatively small amount (≤0.3mg) of HSA. Because of specific regulatory requirements and limited suppliers of HSA acceptable for human use, there was a need to replace HSA with recombinant human albumin (rHA) to mitigate any potential risk to the availability of M-M-R(®)II. Two different formulations of M-M-R(®)II manufactured using either rHA or HSA were clinically evaluated for safety and immunogenicity when administered as a 2-dose regimen to healthy children 12-18 months and 3-4 years of age. Adverse events, including those indicative of a possible hypersensitivity reaction, were collected for 42 days after each dose. Antibodies to measles, mumps, and rubella were measured before and approximately 6 weeks after dose 1. Antibodies to rHA were measured before and approximately 6 weeks after dose 1 and dose 2. Antibody seroconversion rates to measles, mumps, and rubella were 97.0%, 99.5%, and 99.7%, respectively, for recipients of M-M-R(®)II with rHA and 97.2%, 97.9%, and 99.6%, respectively, for recipients of M-M-R(®)II with HSA, and geometric mean titers to all 3...Continue Reading
References
Oct 1, 1975·Clinical Pediatrics·V W WaltersM T Kenny
May 1, 1991·Vaccine·B Christenson, M Böttiger
Oct 1, 1988·Vaccine·M JustN Scheiermann
Nov 14, 1987·British Medical Journal·M BöttigerA Strandell
Apr 1, 1985·Statistics in Medicine·O Miettinen, M Nurminen
Jan 1, 1974·Cell and Tissue Research·F Pietruschka
Jan 18, 1995·JAMA : the Journal of the American Medical Association
Nov 24, 1994·The New England Journal of Medicine·H PeltolaK Cantell
May 1, 1993·The Pediatric Infectious Disease Journal·D P Greenberg
Nov 14, 1997·Pediatrics·R L DavisR Chen
Apr 24, 1999·Haemophilia : the Official Journal of the World Federation of Hemophilia·S SeremetisD Hurst
Aug 7, 1999·Revista Do Instituto De Medicina Tropical De São Paulo·G GonçalvesH R Andrade
Jun 16, 2000·Applied Microbiology and Biotechnology·H A KangS K Rhee
Mar 20, 2001·Archives of Pediatrics & Adolescent Medicine·R L DavisUNKNOWN Vaccine Safety Datalink Team
Feb 15, 2002·The New England Journal of Medicine·Nicole CasadevallPatrick Mayeux
Apr 23, 2002·Haemophilia : the Official Journal of the World Federation of Hemophilia·C RothschildW Effenberger
Dec 17, 2004·Journal of Clinical Pharmacology·Dietrich BosseFritz Schindel
Aug 12, 2005·The Pediatric Infectious Disease Journal·Henry ShinefieldUNKNOWN Dose Selection Study Group for Proquad
Feb 3, 2006·Pediatrics·Keith S ReisingerUNKNOWN Protocol 014 Study Group for ProQuad
Feb 9, 2006·Biologicals : Journal of the International Association of Biological Standardization·Kaoru Kobayashi
Mar 29, 2006·The Pediatric Infectious Disease Journal·Henry ShinefieldUNKNOWN 013 Study Group for ProQuad
Jun 29, 2006·The Pediatric Infectious Disease Journal·Jay M LiebermanUNKNOWN Consistency Lot Study Group for ProQuad
Nov 26, 2009·Journal of Pediatric Nursing·Brandi D NewbyCheryl I Soukoroff
Mar 28, 2012·Journal of Pain & Palliative Care Pharmacotherapy·UNKNOWN Centers for Disease Control and Prevention, Public Health Service, U.S. Department Health
Sep 11, 2012·Vaccine·Fabio LievanoStanley A Plotkin